CP and dengue disease: In the context of generating the dengue vaccine candidates, the versatility of the VLP platforms allows for the exploration of VLPs derived directly from DENV (DENV VLPs) [180,245,246,247] or the use of other viral CP-based VLPs from sources such as mammalian viruses [182,248], plant viruses [50,51,249], or bacteriophages [77,250,251].